Harbin Medisan Pharmaceutical Co., Ltd.

Main purpose: According to the relevant provisions of bioequivalence test, aripiprazole orodisintegrating tablets (trade name: Abilify, specification: 10mg) with Otsuka Pharmaceutical Netherlands B.V. as the licensee were selected as the reference preparation, and the test preparation aripiprazole orodisintegrating tablets (specification: 10mg) produced and provided by Harbin Sanlian Pharmaceutical Co., Ltd. were subjected to human bioequivalence test under the condition of postprandial administration, the pharmacokinetic characteristics of the test preparation and the reference preparation were compared, and the bioequivalence of the two preparations under the condition of postprandial administration was evaluated. Secondary purpose: Observe the safety of oral administration of the test preparation aripiprazole orodisintegrating tablets (specification: 10mg) and the reference preparation aripiprazole orodisintegrating tablets (trade name: Abilify, specification: 10mg) in healthy subjects; Evaluate the palatability of aripiprazole orodisintegrating tablets in healthy Chinese subjects, and provide a basis for the taste of aripiprazole orodisintegrating tablets.

The main purpose of the study is to investigate the absorption rate and extent of the test preparation and the reference preparation under fasting and postprandial conditions after a single oral dose of vardenafil hydrochloride orodisintegrating tablets (test preparation, produced by Harbin Sanlian Pharmaceutical Co., Ltd.) and vardenafil hydrochloride orodisintegrating tablets (reference preparation, produced by Alembic Pharmaceuticals Inc.) was taken by healthy subjects in the fasting/postprandial state, and to evaluate whether the test preparation and the reference preparation are bioequivalent. The secondary purpose of the study is to observe the safety of the test preparation and the reference preparation of vardenafil hydrochloride orodisintegrating tablets in healthy subjects.

Main purpose of the study: According to the relevant provisions of bioequivalence tests, Betahistine Mesylate Tablets (trade name: Minshilang®, specification: 6mg) of which Eisai (China) Pharmaceutical Co., Ltd. is the licensee was selected as the reference preparation, and the test preparation Betahistine Mesylate Tablets (specification: 6mg) produced by Lanxiha Sanlian Pharmaceutical Co., Ltd. and provided by Beijing Ha Sanlian Technology Co., Ltd. were subjected to human bioequivalence tests for fasting and postprandial administration, to compare whether the absorption rate and degree of the drug in the test preparation were within the acceptable range with the reference preparation, and to evaluate the bioequivalence of the two preparations under fasting and postprandial administration conditions. Secondary purpose of the study: To observe the safety of oral administration of the test preparation Betahistine Mesylate Tablets and the reference preparation Betahistine Mesylate Tablets in healthy subjects.